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Abstract
Background: Plasmodium vivax has a dormant hepatic stage, called the hypnozoite, which can cause relapse
months after the initial attack. For 50 years, primaquine has been used as a hypnozoitocide to radically cure
P. vivax infection, but major concerns remain regarding the side-effects of the drug and adherence to the 14-day
regimen. This study examined the effectiveness of using the directly-observed therapy (DOT) method for the
radical treatment of P. vivax malaria infection, to prevent reappearance of the parasite within the 90-day follow-up
period. Other potential risk factors for the reappearance of P. vivax were also explored.
Methods: A randomized trial was conducted from May 2007 to January 2009 in a low malaria transmission area
along the Thai-Myanmar border. Patients aged ≥ 3 years diagnosed with P. vivax by microscopy, were recruited. All
patients were treated with the national standard regimen of chloroquine for three days followed by primaquine for
14 days. Patients were randomized to receive DOT or self-administered therapy (SAT). All patients were followed for
three months to check for any reappearance of P. vivax.
Results: Of the 216 patients enrolled, 109 were randomized to DOT and 107 to SAT. All patients recovered without
serious adverse effects. The vivax reappearance rate was significantly lower in the DOT group than the SAT group
(3.4/10,000 person-days vs. 13.5/10,000 person-days, p = 0.021). Factors related to the reappearance of vivax malaria
included inadequate total primaquine dosage received (< 2.75 mg/kg), duration of fever ≤ 2 days before initiation
of treatment, parasite count on admission ≥ 10,000/µl, multiple P. vivax-genotype infection, and presence of
P. falciparum infection during the follow-up period.
Conclusions: Adherence to the 14-day primaquine regimen is important for the radical cure of P. vivax malaria
infection. Implementation of DOT reduces the reappearance rate of the parasite, and may subsequently decrease
P. vivax transmission in the area.
Background
Globally, over 3 billion people live in areas at risk of
malaria infection; about one billion of these live in
countries outside Africa, where malaria transmission is
low and Plasmodium vivax is most prevalent [1,2].
Unlike Plasmodium falciparum, P. vivax infection rarely
develops into complicated malaria and death is unusual.
However, P. vivax has a dormant stage (the hypnozoite)
that persists in the human liver and may cause relapse
weeks, months, or even years later. Therefore, P. vivax
infection is considered to have greater impact on mor-
bidity than mortality, resulting in significant social and
economic burdens [1]. Moreover, it is very difficult to
control P. vivax transmission, because gametocytes
appear almost simultaneously with schizonts.
In Thailand, most malaria cases are caused by P. falci-
parum and P. vivax. The incidence ratio of P. falci-
parum malaria to P. vivax malaria is almost 1:1 [3].
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primaquine is the standard treatment regimen to eradi-
cate P. vivax parasites in the bloodstream and hypno-
zoites in the liver. Although chloroquine resistance has
been reported in Papua New Guinea and Indonesia [4],
it is still effective in Thailand [5-8]. Occasional failure of
the standard primaquine therapy (15 mg daily for 14
days) to prevent relapse has been observed [9-15]. How-
ever, primaquine resistance has not been confirmed. In
Thailand, the relapse rates at day 28 are about 50%
without primaquine therapy [16], and about 20% with
standard primaquine therapy [17]. Relapse has not been
observed among patients receiving high-dose prima-
quine therapy (30 mg daily for 14 days) [16].
A number of factors are reportedly associated with
relapse, or the reappearance of P. vivax, including inade-
quate primaquine dosage [12,14], high parasitaemia at
diagnosis, short duration of symptoms prior to diagnosis
[14], presence of gametocytes on admission [18], age,
and gender [6,14,19,20]. Because the radical cure of
P. vivax hypnozoites requires 14 days of primaquine
therapy, adherence to the drug regimen may greatly
affect the prevention of relapse. Unfortunately, the effect
of patient adherence on 14-day primaquine treatment,
and its relation to preventing parasite reappearance, is
not well-documented.
Directly-observed therapy (DOT) is an effective strat-
egy to ensure patient adherence to long-term che-
motherapy. Currently, DOT is the main strategy for
treating tuberculosis (TB) in many countries and its suc-
cess has been widely reported [21]. However, the effec-
tiveness of DOT for 14-day primaquine therapy in vivax
malaria has not been studied thoroughly, particularly in
malaria-tuberculosis co-endemic countries. Here, a ran-
domized control trial was conducted to determine the
effectiveness of DOT for 14-day primaquine administra-
tion, and the reappearance of P. vivax in a low malaria
transmission area along the Thai-Myanmar border.
Other potential risk factors for the reappearance of
P. vivax after radical treatment were also explored.
Methods
Study site
The study was conducted between May 2007 and Janu-
ary 2009 at the Rajanagarindra Tropical Disease Interna-
tional Centre (RTIC), Tanaosri Subdistrict, Suan Phung
District, Ratchaburi Province, Thailand. The area is situ-
ated 100 km west of Bangkok near the Myanmar border.
The study area comprised seven hamlets with about
3,500 residents. The population in the area is composed
of four ethnic groups, Karen (85%), Thai (14%), Mon
and Burmese (1%). For a decade, the RTIC clinic has
provided free malaria diagnosis and treatment for the
local community. Patients from other hamlets also routi-
nely seek malaria treatment here.
Study participants
Patients aged ≥ 3 years with microscopically-confirmed
P. vivax infection were included in the study provided
they or their guardians gave informed consent. Patients
with microscopically confirmed mixed infections of
P. vivax with other Plasmodium species, severe malaria,
pregnant or lactating were excluded. G6PD deficient
patients were included in this study, since the most com-
mon G6PD mutations in Thailand are G6PD Mahidol
and G6PD Viangchan [22], which have been reported to
be relatively safe for primaquine standard therapy [23].
This study was approved by the Ethics Committee of the
Faculty of Tropical Medicine, Mahidol University.
Randomization and treatment
To compare the effectiveness of directly observed ther-
apy (DOT) with self-administered therapy (SAT), study
participants were randomly assigned to either a DOT
group or a SAT group using the block randomization
method with a block size of four. Patients assigned to
the SAT group, upon diagnosis, were given anti-malar-
ials for self-administration with standard instructions in
taking the drugs. Patients assigned to the DOT group
were visited daily at home by RTIC staff until the full
course was taken.
All patients were treated with the national standard
regimen for vivax malaria, as recommended by the
Malaria Control Program of Thailand (chloroquine
1,500 mg base over three days, followed by primaquine
15 mg daily for 14 days). G6PD screening is not
required before giving the primaquine treatment. Chlor-
oquine and primaquine doses were adjusted accordingly
for patients under 14 years of age: for 8-13 years old,
chloroquine 900 mg base over three days, and prima-
quine 10 mg daily for 14 days; for 3-7 years old, chloro-
quine 750 mg base over three days, and primaquine 5
mg daily for 14 days. If P. vivax parasitaemia reappeared
within three months, the daily primaquine dose was
increased to twice the initial dose.
Data collection
Baseline demographic and clinical data were gathered by
interview. Finger-prick blood samples were collected on
filter paper to examine for G6PD mutations and parasite
genotype. All patients were followed for 90 days with
Day 0 defined as the first day of drug administration.
During the follow-up period, patients from both
groups were visited by RTIC staff at Days 7, 14, 28, 60,
and 90, to examine for P. vivax and other Plasmodium
parasitaemia. Patients were instructed to visit RTIC if
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iod. At Days 7 and 14, patients in the SAT group were
asked whether they took their anti-malarials as
instructed. Upon microscopic confirmation of P. vivax
reappearance, a finger-prick blood sample was taken to
determine the parasite genotype for comparison against
baseline genotype(s).
DNA extraction
DNA was extracted from finger-prick blood samples on
filter paper, using a QIAamp DNA Mini Kit according
to the manufacturer’s instructions (Qiagen, Germany).
G6PD mutation
The two most common G6PD mutations in the Karen
population, G6PD Mahidol and G6PD Viangchan, were
examined using polymerase chain reaction (PCR) and
restriction fragment length polymorphism analysis of
the PCR products (PCR-RFLP), as described by Nuch-
prayoon et al [24] with slight modification, as follows:
the PCR reaction was carried out in a 20 µl reaction
volume containing 2.5 mM MgCl2; for PCR-RFLP, 10 µl
of the PCR product were digested with an appropriate
restriction enzyme (New England Biolabs Inc., UK) in a
total volume of 20 µl.
Parasite genotyping
The pvcs and pvmsp3-a genes were used. Nested PCR
and PCR-RFLP were carried out, following the previously
described procedure [25,26]. For the pvcs gene, five size
v a r i a n t s :6 5 0 ,6 8 0 ,7 0 0 ,7 2 0 ,a n d7 5 0b a s ep a i r sw e r e
c o d e da sa ,b ,c ,d ,a n de ,r e s p e c t i v e l y .V Kt y p ew a s
labelled as VK210 or VK247 according to the results of
PCR-RFLP. For the pvmsp3-a gene, three size variants:
1,900, 1,500 and 1,100 base pairs, were labelled A, B, and
C, respectively. For PCR-RFLP analysis by Hha I, diges-
tion types were labelled as h1-h14 (as sizes A, B, and C:
h1-h10, h11-h12, and h13-h14, respectively). Digestion
types by Alu I were labelled as a1-a24 (as size A, B, and
C: a1-a16, a17-a19, and a20-a24, respectively).
Multiplicity of infection (MOI) was estimated by geno-
typing results in two loci: the pvcs gene and the pvmsp3-
a g e n e .I tw a sd e f i n e da st h em i n i m u mn u m b e ro f
combinations of MOI at each locus. In each gene, MOI
was estimated by the number of bands on a PCR product
gel picture. In the case of the pvcs gene, even if only one
band was observed on the PCR product picture, it was
estimated that the MOI was two when the results of
PCR-RFLP showed both VK types: VK210 and VK247.
Statistical analysis
The baseline characteristics of the patients in the SAT
and DOT groups were compared using chi-square, Stu-
dent’st ,a n dM a n n - W h i t n e yU tests, depending on the
type and distribution of the data. Age was categorized
into three groups, 3-7 years, 8-13 years, and ≥14 years,
according to the age-adjusted primaquine regimen. The
cut-off level of the total primaquine dose per body
weight (2.75 mg/kg) was used to indicate inadequate
dose (< 2.75 mg/kg), as reported in a previous study
[14]. The incidence rates of P. vivax reappearance
observed among patients in the SAT and DOT groups
were calculated and compared. Cox’s proportional
hazard regression modelling was used to examine fac-
tors related to the first reappearance of P. vivax malaria
parasitaemia. The analysis was performed using Stata
8.0 computer package (StataCorp., USA).
Results
Enrolment and baseline characteristics of the patients
A total of 216 patients were enrolled between 26 May
2007 and 31 October 2008 and randomized into either the
SAT group (107 patients) or the DOT group (109
patients). Over half of the patients (n = 123; 57%) were
enrolled into the study during the high malaria transmis-
sion season in the study area (April to June). G6PD muta-
tions were found in 22% of the patients (homozygous, 2%;
hemizygous, 9%; heterozygous, 11%). All mutations were
G6PD Mahidol. Despite the random allocation, patients in
the DOT group were younger than those in the SAT
group (Mann-Whitney U test: p = 0.004 for continuous
age variable, chi-square test: p=0.001 for age groups);
other baseline characteristics were comparable between
DOT and SAT groups (Table 1).
Incidence rate of the reappearance of P. vivax
parasitaemia
Of the 216 patients, 187 (87%) completed their 90-day
follow-up period; 90 (83%) patients and 97 (91%) patients
were in the DOT and SAT groups, respectively. Reap-
pearance of P. vivax parasitaemia during follow-up was
observed in 15 patients (8%). The overall incidence rates
of P. vivax parasitaemia reappearance (per 10,000 per-
son-days) at Days 28, 60, and 90, were 1.67, 4.78, and
8.43, respectively. The median (min-max) time to reap-
pearance of P. vivax parasitaemia was 68 (13-90) days.
T h er a t eo fP. vivax reappearance in the DOT group
was significantly lower than the SAT group (Figure 1).
The reappearance rates at Days 28, 60, and 90, were 0,
3.18, and 3.37, respectively, in the DOT group, com-
pared with 3.35, 6.39, and 13.49 in the SAT group.
Factors related to the reappearance of P. vivax malaria
parasitaemia
In the univariate analysis, treatment group, total prima-
quine dose per bodyweight, parasite count on admission,
and multiple P. vivax-genotype infection were significantly
associated with reappearance of P. vivax malaria (Table 2).
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appearance of P. falciparum parasitaemia during the fol-
low-up period and risk of P. vivax reappearance (crude
HR 4.01, 95% CI 0.90-17.77). G6PD mutation status,
infected P. vivax genotype (VK type), gender, presence of
gametocyte at baseline, and P. vivax acquisition month did
not show statistically significant associations.
The significant variables from the univariate analysis, with
two additional variables (age group and number of days
with fever before start of treatment), were included in the
multivariate model (Table 2). The reappearance rate for P.
vivax was significantly higher in the SAT group, compared
with the DOT group (adjusted HR 6.21, 95% CI 1.39-
27.79). Children aged 8-13 years had the lowest risk of P.
vivax reappearance. Interestingly, the reappearance rate
appeared to be about six times lower among patients who
received late treatment, i.e. pre-treatment duration of fever
≥3 days, compared with early treatment (adjusted HR 0.16,
95% CI 0.04-0.68). Inadequate total primaquine dose was
also associated with reappearance as those who received a
total primaquine dose < 2.75 mg/kg were about 10 times
more likely to have a subsequent P. vivax attack than those
who received a total primaquine dose ≥ 2.75 mg/kg. In
addition, parasite-related factors including baseline parasite
count ≥ 10,000 /µl, multiple P. vivax-genotype infection,
and P. falciparum detected during follow-up were positively
associated with risk of P. vivax reappearance (Table 2).
Adherence to 14-day primaquine treatment among the
SAT group
Adherence to primaquine treatment was determined by
interviewing patients in the SAT group (response rate =
94%) at Days 7 and 14. Fifteen of 101 patients (15%)
reported that they have not taken the drug at least once
during the 14 days of treatment. Patients who missed a
primaquine dose or doses tended to have a higher risk
of reappearance of P. vivax parasitaemia than those who
took a complete14-day course (13% vs. 9%), although
this difference was not statistically significant.
Non-adherence during Week 1 of treatment was
reported by 6% of patients, whereas 12% of patients
reported that they missed at least one dose of primaquine
during Week 2. The median number of missed doses was
more than four times higher in the Week 2 of treatment
than Week 1. Interestingly, patients who received the treat-
ment within two days of an acute attack tended to non-
adhere to treatment in Week 2, compared with Week 1
(17% vs. 2%; Fisher’s exact test, p = 0.030), whereas those
who came to the clinic >2 days after the initial attack did
not show any difference in treatment adherence for Weeks
1 or 2 (7% vs. 9%). Non-adherence was more likely to be
reported by males and in children aged 8-13 years,
although the differences were not statistically significant.
Comparison of genotype in primary attack and
reappearance of parasitaemia
The parasite genotypes in the primary and subsequent
attacks for 15 patients who had reappearance of P. vivax
Table 1 Baseline characteristics, by treatment group (N =
216)
Variables DOT SAT
Number of patients n = 109 n = 107
Female; N (%) 45 (41) 41 (38)
Age group; N (%)
3-7 years 34 (31) 20 (19)
8-13 years 26 (24) 13 (12)
≥14 years 49 (45) 74 (69)
G6PD mutation status; N (%)
Wild-type 81 (75) 84 (81)
G6PD Mahidol: Homozygous 2 (2) 2 (2)
G6PD Mahidol: Hemizygous 9 (8) 11 (10)
G6PD Mahidol: Heterozygous 16 (15) 7 (7)
Body temperature at Day 0 (°C); Mean ± SD 37.8 ± 1.2 37.8 ± 1.2
Duration of fever pre-treatment; N (%)
0-2 days 62 (57) 50 (47)
3+ days 46 (43) 57 (53)
Parasite count at Day 0 (/µl); Geometric
mean (range)
1,890
(32-75600)
2,533
(32-400000)
Gametocyte presence at Day 0; N (%) 45 (41) 37 (35)
Gametocyte count at Day 0 (/µl)
; Geometric
mean (range)
141 (16-
1600)
141
(16-8160)
P. vivax genotype (pvcs gene) infected at
Day 0; N (%)
VK210 95 (91) 84 (80)
VK247 4 (4) 12 (11)
VK210&VK247 5 (5) 9 (9)
Number of P. vivax genotype infections;N
(%)
Single 85 (82) 84 (80)
Multiple infection 19 (18) 21 (20)
Figure 1 Nelson-Aalen cumulative hazard curves, by treatment
group.
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amplify, and three blood samples of either primary or
subsequent attacks from three patients were missing.
The P. vivax genotype patterns of the remaining 10
patients are summarized in Table 3. Three patients had
the same P. vivax genotypes in both primary attack and
reappearance. Five patients showed different genotype
patterns in the primary episode and subsequent attack.
Among the patients who experienced reappearance of
P. vivax malaria, the type B pvmsp3-a gene was not
found in either the parasites responsible for the primary
attack nor the reappearance. The proportion of pvcs
gene genotype, VK type (regardless of gene size), and
the pvmsp3-a gene size of the P. vivax parasite in the
primary attack and in the reappearance of parasitaemia
did not reveal any significant difference.
Discussion
Adherence to a 14-day primaquine regimen for the radical
treatment of P. vivax hypnozoites, especially after symp-
toms have subsided, is a serious concern. In this study we
found the non-adherence rate in treatment Week 2 was
Table 2 Crude and adjusted hazard ratio (HR) and 95% confidence interval (CI) for factors related to P. vivax
reappearance
Variables Reappearance
N (%)
Crude HR
(95% CI)
Adjusted HR*
(95% CI)
Treatment group
DOT 3 (2.8) 1 1
SAT 12 (11.2) 3.98 (1.12-14.09) 6.21 (1.39-27.79)
Age group
3-7 years 6 (11.1) 1 1
8-13 years 1 (2.6) 0.21 (0.03-1.72) 0.02 (0.0008-0.54)
≥14 years 8 (6.5) 0.60 (0.21-1.72) 0.62 (0.17-2.32)
Duration of fever pre-treatment
0-2 days 11 (9.8) 1 1
3+ days 4 (3.9) 0.38 (0.12-1.21) 0.16 (0.04-0.68)
Total primaquine dose/body weight
≥2.75 mg/kg 13 (6.1) 1 1
<2.75 mg/kg 2 (50.0) 8.39 (1.89-37.22) 10.45 (2.02-54.03)
Parasite count at Day0
<10000 /µl 8 (4.3) 1 1
≥10000 /µl 6 (20.0) 4.87 (1.69-14.04) 5.43 (1.59-18.54)
Multiplicity of P. vivax genotype infection 8 (4.7) 1 1
Single 6 (15.8) 5.97 (2.07-17.23) 4.81 (1.53-15.16)
Multiple
P. falciparum infection post-treatment for P. vivax
No 13 (6.3) 1 1
Yes 2 (22.2) 4.01 (0.90-17.77) 13.66 (1.36-137.64)
Gender
Male 10 (7.7) 1 -
Female 5 (5.8) 0.78 (0.27-2.28)
Presence of gametocyte
No 10 (7.5) 1 -
Yes 4 (4.9) 0.63 (0.19-2.01)
pvcs gene genotype
VK210 12 (6.7) 1 -
VK247 1 (6.3) 1.10 (0.14-8.49)
VK210&VK247 1 (7.1) 1.06 (0.14-8.13)
G6PD mutation status
Wild-type 12 (7.3) 1 -
G6PD Mahidol Homozygote 0 -
G6PD Mahidol Hemizygote 2 (10.0) 1.33 (0.30-5.93)
G6PD Mahidol Heterozygote 1 (4.3) 0.62 (0.081-4.78)
*Adjusted for variables included in the multivariate Cox regression model.
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is probably an underestimate since some patients may not
have reported missing a dose. Moreover, the home visit on
Day 7 among the SAT group may increase the adherence
rate among patients in that group, which further underes-
timates the reported non-adherence rate, compared with
the real situation. The DOT method ensures that patients
complete the full course of treatment. The findings of this
study suggest that, compared with self-administration,
DOT increases the likelihood of radical cure in P. vivax
malaria infection. Patients with supervised therapy were
about six times less likely to have P. vivax reappearance
within the 90-day follow-up period. The protective effect
of the DOT is likely to be larger than the estimate, if the
underestimation of non-adherence rate in the SAT group
was taken into account.
This study also showed that total primaquine dose per
body weight < 2.75 mg/kg was associated with reappear-
ance of P. vivax parasitaemia. This indicates that an inade-
quate dose of primaquine during the primary attack may
increase the risk of a subsequent P. vivax attack. In prac-
tice, weight-independent doses are used because of the dif-
ficulties of using weight-adjusted doses in the field.
Therefore, total primaquine dose per body weight varies
considerably; e.g., patients who weigh 60 kg and 80 kg
receive 3.5 mg/kg and 2.6 mg/kg, respectively, adhering to
the adult regimen of “15 mg of primaquine daily for 14
days”. Treatment failure due to an inadequate dose may be
misinterpreted as drug resistance. This misinterpretation
may occur not only between individuals, but also between
areas because average body weight differs between coun-
tries and ethnic groups. The average bodyweight of
patients in this study aged ≥ 14 years was 52.7 kg
compared to 67.3 kg in a study in Brazil [14]. Therefore,
weight-adjusted doses should be considered when assessing
whether primaquine-resistant P. vivax is present. In addi-
tion, weight-based dosing schedules for primaquine should
be more appropriate than the existing nationwide age-
adjusted guideline for primaquine treatment due to a wide
range of average body weight among different populations.
Poor adherence was more likely to be reported by
males or children aged 8-13 years. While children aged
8-13 years showed the highest rate of non-adherence to
primaquine treatment, they had the lowest rate of reap-
pearance of P. vivax parasitaemia. This may be
explained by the relatively high dose of primaquine that
children aged 8-13 years received compared with the
other age groups (age group 3-7 years: 4.74 ± 0.95 mg/
kg, 8-13 years: 5.07 ± 0.95 mg/kg, ≥ 14 years: 4.19 ±
0.98 mg/kg). Even if these children skipped a dose once
or twice, the total primaquine dose would still be suffi-
cient to constitute a “therapeutic dose”.
Higher multiple P. vivax-genotype infections were asso-
ciated with increased risk of the reappearance of P. vivax
parasitaemia, which may be the result of acquired geno-
type-specific host immunity [27]. Patients who suffer from
mixed genotype infections may develop genotype-specific
acquired immunity to only the dominant genotype in the
primary attack. As a consequence, the low-level genotype
in the primary attack could reappear more easily than the
dominant genotype which may be suppressed by acquired
genotype-specific immunity. In contrast, patients with a
single genotype infection, whose acquired immunity devel-
ops during primary infection, can suppress the reappearing
parasites that are caused by hypnozoites with the same
genotype as those in the primary attack. In this study, at
Table 3 Comparison of P. vivax genotypes in primary attack and reappearance(s) (N = 10)
Case Primary attack First reappearance Second reappearance
Parasite count (/µl) pvcs, pvmsp3a
gene
Day Parasite count (/µl) pvcs, pvmsp3a
gene
Day Parasite count (/µl) pvcs, pvmsp3a
gene
Same* 1 >400000 c_VK210, A_h8a7 68 160 c_VK210, A_h8a7 91
(159)
800 c_VK210, A_h8a7
2 8800 be_VK210, A_h6a7 30 6640 be_VK210, A_h6a7 29 (59) 7440 Missing data
3 3080 c_VK210, A_h1a2 68 16480 c_VK210, A_h1a2
Different
‡ 4 29360 c_VK247, A_hm
†am
† 89 400 b_VK210, A_h1a15
5 30640 b_VK210, A_h1a4 90 22880 b_VK210, A_h4a6
6 1280 d_VK210&247, A_h2a3 52 112 c_VK210, A_h5a8
7 7440 ab_VK210, AC
§ 52 12320 b_VK210, A_h7a2
8 19360 be_VK210, A_h3a1 81 33440 b_VK210, A_h1a4
Ambiguous 9 16560 a_VK210, AC
§ 68 2040 c_VK210, C_h1a3
10 16000 c_VK210, A_hm
†a2 59 2720 c_VK210, A_h5a2 60
(119)
64 c_VK210, A_h1a2
*For two markers, all of the gel picture patterns in the primary-attack parasite and reappearance parasite were the same.
†Digestion pattern not classified, because sum of PCR-RFLP fragment sizes exceeded uncut gene size.
‡For two markers, at least one band in the gel picture patterns in the primary attack and in the reappearance parasite was different.
§Digestion pattern not classified because of multiple-genotype infection classified by PCR result for the pvmsp3-a gene.
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patients who had P. vivax reappearance; however, the con-
ventional PCR used to analyse the genotype in this study
was unable to identify the dominant genotype within an
individual host. Using real-time PCR to determine the pro-
portion of each genotype in the primary attack may help
understand whether the dominant or the low-level geno-
type actually reappears.
The risk of the reappearance of P. vivax in this study
was related to the level of parasitaemia on admission,
consistent with a previous study from Brazil [14]. In
Thailand, the major strain of the P. vivax parasite is the
Chesson strain, which can produce about equal numbers
of hepatic schizonts and hypnozoites [28]. This ratio
remains constant regardless of the initial number of spor-
ozoites inoculated [29]. Therefore, the absolute number
of hypnozoites should increase with parasite count,
which subsequently increases the probability of relapse.
The duration of fever before initial treatment was signifi-
cantly associated with the reappearance of P. vivax.
Patients who received early treatment (≤ 2d a y s )w e r e
more likely to develop a repeat P. vivax attack. This find-
ing is possibly explained by the relationship between the
timing of primaquine administration and the growth and
stabilization of the hypnozoites. Research has not yet con-
firmed exactly how primaquine works on hypnozoites.
However, primaquine is thoug h tt oa f f e c tt h ep a r a s i t e
mitochondrial electron transport chain [30]. Because hyp-
nozoites are “dormant”, they cannot replace their damaged
mitochondria and become extinct [31]. The hypnozoites
can be recognized three days after the host has been
infected with P. vivax,a n dt h es i z eo fh y p n o z o i t e s
becomes stable 7-15 days after infection [32-34]. However,
it is unclear when the hypnozoites’ function becomes “dor-
mant”. Since the incubation period of P. vivax is 12-17
days, some hypnozoites may not have stabilized yet during
the first few days after the acute attack. Therefore, if pri-
maquine administration is started earlier after an initial
attack, the drug’s effects may be less than expected
because the hypnozoites are not “dormant” enough. The
association between relapse rate and timing of treatment
may be explained by the difference in the non-adherence
rate between patients treated early and those who had
treatment delay. In this study, non-adherence was found
in 13% of patients who received late treatment, as com-
pared with 17% of those with early treatment. However,
this difference was not statistically significant.
The appearance of P. falciparum parasitaemia during the
follow-up period was found to be a risk factor. However,
the sample size was too small to obtain reliable results.
Further research is needed to confirm these findings.
The pvcs and pvmsp3-a gene loci were used to compare
the parasite genotypes in the primary attack and the reap-
pearance of parasitaemia. The results showed a similar
genotype pattern in the primary attack and the reappear-
ance of parasitaemia. No particular genotypes were found
to be associated with reappearance. Recently, P. vivax gen-
ome sequencing has revealed some genes that are likely
related to dormancy or differentiation [35], and may be
associated with risk of relapse. However, future research
using these genes is needed to explore the association. In
terms of comparison of genotypes between primary and
subsequent attacks, most of the genotypes observed in the
parasites in a primary attack were not exactly the same as
the reappearance parasites. The genotypic difference in
the reappearing parasite cannot distinguish relapse from
heterozygous hypnozoite or re-infection [27]. Since the
episodes of reappearance were observed within 90 days of
the initial attack, when the risk of relapse was highest in
this low malaria-transmission area, the parasitaemia reap-
pearances observed were most likely due to relapse.
Conclusions
This study supports the supposition that poor adherence
to 14-day primaquine treatment can affect the effective-
ness of radical therapy for P. vivax malaria infection; DOT
should be considered for improving compliance to 14-day
primaquine treatment, since it reduces the risk of relapse.
In areas where both tuberculosis and vivax malaria are
prevalent, integrating DOT for P. vivax with existing DOT
system for treatment of tuberculosis, where health workers
had been trained for house visit to deliver drugs, should
have a major impact on reducing disease transmission and
on the financial burden of these two diseases. Inadequate
dose of primaquine is also one of the most important fac-
tors for radical cure of P. vivax; weight-adjusted doses
should be considered and the most practical way to apply
weight-adjusted doses should be sought.
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